Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to Monte Rosa Therapeutics conference call to discuss the company's pipeline updates and clinical results. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference call is being recorded. It is now my pleasure to introduce Andrew Funderburk, Senior Vice President, Investor Relations, and Strategic Finance at Monterosa. Thank you, Andrew. You may begin. Thank you. Good morning, everyone, and thank you for joining our conference call to discuss the clinical and preclinical updates across our pipeline. With us on today's call are Marcus Wormuth, Chief Executive Officer, Philip Iancu, Chief Medical Officer, Sharon Townsend, Chief Scientific Officer, and Phil Nixon, Chief Business and Legal Officer. Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are based on our current beliefs, plans, and expectations and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please refer to our annual report and other filings we make with the SEC for our risk factors and other information. With that, I'll turn the call over to Marcus. Thank you, Andrew, and thanks, everyone, for joining us this morning. It's a real pleasure to provide today exciting updates across our clinical and preclinical programs. I kick it off by just outlining some of the highlights we will go through in this call today. First, we'll talk about results from our Phase 1 Healthy Volunteer Study of MRT6160, which very clearly support a path into broad Phase 2 development of this asset. Phillip will discuss these resu...